Of the 100 responses received, about one third were supportive of the proposal, one third opposed and one third were not opposed but raised issues. This was the position put to the Committee on Safety of Medicines (CSM), which also had access to the full responses when giving its advice. The consultation raised no issues not already considered by the CSM when their advice to consult on making simvastatin 10 milligrammes (mg) available over the counter was formulated. An error in the summary placed on the website following the announcement of the decision to allow simvastatin 10 mg to be sold in pharmacies had no bearing on the robustness of the deliberations of the CSM.
Responses received to the consultation on the proposed reclassification of simvastatin as an over-the-counter medicine have been made available electronically or summarised on the Medicines and Healthcare products Regulatory Agency's (MHRA) website at:
To ensure complete transparency, the MHRA publishes the responses to all such consultations—most recently for chloramphenicol eye drops.